Mood and cognition in leucine‐rich repeat kinase 2 G2019S Parkinson's disease
Identifieur interne : 000B05 ( Main/Corpus ); précédent : 000B04; suivant : 000B06Mood and cognition in leucine‐rich repeat kinase 2 G2019S Parkinson's disease
Auteurs : Vicki Shanker ; Mark Groves ; Gary Heiman ; Christina Palmese ; Rachel Saunders-Pullman ; Laurie Ozelius ; Deborah Raymond ; Susan BressmanSource :
- Movement Disorders [ 0885-3185 ] ; 2011-08-15.
English descriptors
Abstract
The behavioral and cognitive features of the leucine‐rich repeat kinase G2019S mutation in Parkinson's disease in the Ashkenazi Jewish population are not well described; therefore, we sought to more systematically characterize these features using a semistructured psychiatric interview and neuropsychological testing. Twenty‐one Ashkenazi Jewish patients having the leucine‐rich repeat kinase G2019S mutation were compared with age‐ and sex‐matched Ashkenazi Jewish patients with Parkinson's disease without mutations. Although overall rates of affective disorders were not greater in mutation carriers, the carriers exhibited a 6‐fold increased risk of premorbid affective disorders (odds ratio, 6.0; P = .10), as determined by the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders–IV. Of interest, we identified 2 leucine‐rich repeat kinase carriers with bipolar disorder; no mutation‐negative subjects had this diagnosis. Performance on the Hopkins Verbal Learning Test–Revised, Judgment of Line Orientation, and Frontal Assessment Battery was consistent with previous reports and did not differ between groups. Study findings suggest a possible association between premorbid mood disorders and leucine‐rich repeat kinase Parkinson's disease, warranting further evaluation. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23746
Links to Exploration step
ISTEX:26CEF5A8C585D95DE1DC4C765107ECB1F441C629Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mood and cognition in leucine‐rich repeat kinase 2 G2019S Parkinson's disease</title><author><name sortKey="Shanker, Vicki" sort="Shanker, Vicki" uniqKey="Shanker V" first="Vicki" last="Shanker">Vicki Shanker</name><affiliation><mods:affiliation>Beth Israel Medical Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Groves, Mark" sort="Groves, Mark" uniqKey="Groves M" first="Mark" last="Groves">Mark Groves</name><affiliation><mods:affiliation>Beth Israel Medical Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Heiman, Gary" sort="Heiman, Gary" uniqKey="Heiman G" first="Gary" last="Heiman">Gary Heiman</name><affiliation><mods:affiliation>Rutgers University, Piscataway, New Jersey, USA</mods:affiliation></affiliation></author><author><name sortKey="Palmese, Christina" sort="Palmese, Christina" uniqKey="Palmese C" first="Christina" last="Palmese">Christina Palmese</name><affiliation><mods:affiliation>Beth Israel Medical Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Saunders Ullman, Rachel" sort="Saunders Ullman, Rachel" uniqKey="Saunders Ullman R" first="Rachel" last="Saunders-Pullman">Rachel Saunders-Pullman</name><affiliation><mods:affiliation>Beth Israel Medical Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Ozelius, Laurie" sort="Ozelius, Laurie" uniqKey="Ozelius L" first="Laurie" last="Ozelius">Laurie Ozelius</name><affiliation><mods:affiliation>Mount Sinai Medical Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Raymond, Deborah" sort="Raymond, Deborah" uniqKey="Raymond D" first="Deborah" last="Raymond">Deborah Raymond</name><affiliation><mods:affiliation>Beth Israel Medical Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Bressman, Susan" sort="Bressman, Susan" uniqKey="Bressman S" first="Susan" last="Bressman">Susan Bressman</name><affiliation><mods:affiliation>Beth Israel Medical Center, New York, New York, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:26CEF5A8C585D95DE1DC4C765107ECB1F441C629</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23746</idno><idno type="url">https://api.istex.fr/document/26CEF5A8C585D95DE1DC4C765107ECB1F441C629/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000B05</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Mood and cognition in leucine‐rich repeat kinase 2 G2019S Parkinson's disease</title><author><name sortKey="Shanker, Vicki" sort="Shanker, Vicki" uniqKey="Shanker V" first="Vicki" last="Shanker">Vicki Shanker</name><affiliation><mods:affiliation>Beth Israel Medical Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Groves, Mark" sort="Groves, Mark" uniqKey="Groves M" first="Mark" last="Groves">Mark Groves</name><affiliation><mods:affiliation>Beth Israel Medical Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Heiman, Gary" sort="Heiman, Gary" uniqKey="Heiman G" first="Gary" last="Heiman">Gary Heiman</name><affiliation><mods:affiliation>Rutgers University, Piscataway, New Jersey, USA</mods:affiliation></affiliation></author><author><name sortKey="Palmese, Christina" sort="Palmese, Christina" uniqKey="Palmese C" first="Christina" last="Palmese">Christina Palmese</name><affiliation><mods:affiliation>Beth Israel Medical Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Saunders Ullman, Rachel" sort="Saunders Ullman, Rachel" uniqKey="Saunders Ullman R" first="Rachel" last="Saunders-Pullman">Rachel Saunders-Pullman</name><affiliation><mods:affiliation>Beth Israel Medical Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Ozelius, Laurie" sort="Ozelius, Laurie" uniqKey="Ozelius L" first="Laurie" last="Ozelius">Laurie Ozelius</name><affiliation><mods:affiliation>Mount Sinai Medical Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Raymond, Deborah" sort="Raymond, Deborah" uniqKey="Raymond D" first="Deborah" last="Raymond">Deborah Raymond</name><affiliation><mods:affiliation>Beth Israel Medical Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Bressman, Susan" sort="Bressman, Susan" uniqKey="Bressman S" first="Susan" last="Bressman">Susan Bressman</name><affiliation><mods:affiliation>Beth Israel Medical Center, New York, New York, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-08-15">2011-08-15</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1875">1875</biblScope><biblScope unit="page" to="1880">1880</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">26CEF5A8C585D95DE1DC4C765107ECB1F441C629</idno><idno type="DOI">10.1002/mds.23746</idno><idno type="ArticleID">MDS23746</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>cognition</term><term>depression</term><term>leucine‐rich repeat kinase 2</term><term>mood</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The behavioral and cognitive features of the leucine‐rich repeat kinase G2019S mutation in Parkinson's disease in the Ashkenazi Jewish population are not well described; therefore, we sought to more systematically characterize these features using a semistructured psychiatric interview and neuropsychological testing. Twenty‐one Ashkenazi Jewish patients having the leucine‐rich repeat kinase G2019S mutation were compared with age‐ and sex‐matched Ashkenazi Jewish patients with Parkinson's disease without mutations. Although overall rates of affective disorders were not greater in mutation carriers, the carriers exhibited a 6‐fold increased risk of premorbid affective disorders (odds ratio, 6.0; P = .10), as determined by the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders–IV. Of interest, we identified 2 leucine‐rich repeat kinase carriers with bipolar disorder; no mutation‐negative subjects had this diagnosis. Performance on the Hopkins Verbal Learning Test–Revised, Judgment of Line Orientation, and Frontal Assessment Battery was consistent with previous reports and did not differ between groups. Study findings suggest a possible association between premorbid mood disorders and leucine‐rich repeat kinase Parkinson's disease, warranting further evaluation. © 2011 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Vicki Shanker MD</name><affiliations><json:string>Beth Israel Medical Center, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Mark Groves MD</name><affiliations><json:string>Beth Israel Medical Center, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Gary Heiman PhD</name><affiliations><json:string>Rutgers University, Piscataway, New Jersey, USA</json:string></affiliations></json:item><json:item><name>Christina Palmese PhD</name><affiliations><json:string>Beth Israel Medical Center, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Rachel Saunders‐Pullman MD, MPH</name><affiliations><json:string>Beth Israel Medical Center, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Laurie Ozelius PhD</name><affiliations><json:string>Mount Sinai Medical Center, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Deborah Raymond MS</name><affiliations><json:string>Beth Israel Medical Center, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Susan Bressman MD</name><affiliations><json:string>Beth Israel Medical Center, New York, New York, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>leucine‐rich repeat kinase 2</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>mood</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>depression</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>cognition</value></json:item></subject><articleId><json:string>MDS23746</json:string></articleId><language><json:string>eng</json:string></language><abstract>The behavioral and cognitive features of the leucine‐rich repeat kinase G2019S mutation in Parkinson's disease in the Ashkenazi Jewish population are not well described; therefore, we sought to more systematically characterize these features using a semistructured psychiatric interview and neuropsychological testing. Twenty‐one Ashkenazi Jewish patients having the leucine‐rich repeat kinase G2019S mutation were compared with age‐ and sex‐matched Ashkenazi Jewish patients with Parkinson's disease without mutations. Although overall rates of affective disorders were not greater in mutation carriers, the carriers exhibited a 6‐fold increased risk of premorbid affective disorders (odds ratio, 6.0; P = .10), as determined by the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders–IV. Of interest, we identified 2 leucine‐rich repeat kinase carriers with bipolar disorder; no mutation‐negative subjects had this diagnosis. Performance on the Hopkins Verbal Learning Test–Revised, Judgment of Line Orientation, and Frontal Assessment Battery was consistent with previous reports and did not differ between groups. Study findings suggest a possible association between premorbid mood disorders and leucine‐rich repeat kinase Parkinson's disease, warranting further evaluation. © 2011 Movement Disorder Society</abstract><qualityIndicators><score>5.811</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1352</abstractCharCount><pdfWordCount>3663</pdfWordCount><pdfCharCount>24776</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>179</abstractWordCount></qualityIndicators><title>Mood and cognition in leucine‐rich repeat kinase 2 G2019S Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>26</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>6</total><last>1880</last><first>1875</first></pages><issn><json:string>0885-3185</json:string></issn><issue>10</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/mds.23746</json:string></doi><id>26CEF5A8C585D95DE1DC4C765107ECB1F441C629</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/26CEF5A8C585D95DE1DC4C765107ECB1F441C629/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/26CEF5A8C585D95DE1DC4C765107ECB1F441C629/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/26CEF5A8C585D95DE1DC4C765107ECB1F441C629/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Mood and cognition in leucine‐rich repeat kinase 2 G2019S Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2011</date></publicationStmt><notesStmt><note type="content">*Funding agencies: This project was supported by the Parkinson's Study Group, the National Parkinson's Foundation and the Michael J. Fox Foundation.</note><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report. Full financial disclosures and author roles may be found in the online version of this article.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Mood and cognition in leucine‐rich repeat kinase 2 G2019S Parkinson's disease</title><author><persName><forename type="first">Vicki</forename><surname>Shanker</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Beth Israel Medical Center, 10 Union Square East, Suite 5H, New York, NY 10003, USA</p></note><affiliation>Beth Israel Medical Center, New York, New York, USA</affiliation></author><author><persName><forename type="first">Mark</forename><surname>Groves</surname></persName><roleName type="degree">MD</roleName><affiliation>Beth Israel Medical Center, New York, New York, USA</affiliation></author><author><persName><forename type="first">Gary</forename><surname>Heiman</surname></persName><roleName type="degree">PhD</roleName><affiliation>Rutgers University, Piscataway, New Jersey, USA</affiliation></author><author><persName><forename type="first">Christina</forename><surname>Palmese</surname></persName><roleName type="degree">PhD</roleName><affiliation>Beth Israel Medical Center, New York, New York, USA</affiliation></author><author><persName><forename type="first">Rachel</forename><surname>Saunders‐Pullman</surname></persName><roleName type="degree">MD, MPH</roleName><affiliation>Beth Israel Medical Center, New York, New York, USA</affiliation></author><author><persName><forename type="first">Laurie</forename><surname>Ozelius</surname></persName><roleName type="degree">PhD</roleName><affiliation>Mount Sinai Medical Center, New York, New York, USA</affiliation></author><author><persName><forename type="first">Deborah</forename><surname>Raymond</surname></persName><roleName type="degree">MS</roleName><affiliation>Beth Israel Medical Center, New York, New York, USA</affiliation></author><author><persName><forename type="first">Susan</forename><surname>Bressman</surname></persName><roleName type="degree">MD</roleName><affiliation>Beth Israel Medical Center, New York, New York, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-08-15"></date><biblScope unit="volume">26</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1875">1875</biblScope><biblScope unit="page" to="1880">1880</biblScope></imprint></monogr><idno type="istex">26CEF5A8C585D95DE1DC4C765107ECB1F441C629</idno><idno type="DOI">10.1002/mds.23746</idno><idno type="ArticleID">MDS23746</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The behavioral and cognitive features of the leucine‐rich repeat kinase G2019S mutation in Parkinson's disease in the Ashkenazi Jewish population are not well described; therefore, we sought to more systematically characterize these features using a semistructured psychiatric interview and neuropsychological testing. Twenty‐one Ashkenazi Jewish patients having the leucine‐rich repeat kinase G2019S mutation were compared with age‐ and sex‐matched Ashkenazi Jewish patients with Parkinson's disease without mutations. Although overall rates of affective disorders were not greater in mutation carriers, the carriers exhibited a 6‐fold increased risk of premorbid affective disorders (odds ratio, 6.0; P = .10), as determined by the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders–IV. Of interest, we identified 2 leucine‐rich repeat kinase carriers with bipolar disorder; no mutation‐negative subjects had this diagnosis. Performance on the Hopkins Verbal Learning Test–Revised, Judgment of Line Orientation, and Frontal Assessment Battery was consistent with previous reports and did not differ between groups. Study findings suggest a possible association between premorbid mood disorders and leucine‐rich repeat kinase Parkinson's disease, warranting further evaluation. © 2011 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>leucine‐rich repeat kinase 2</term></item><item><term>mood</term></item><item><term>depression</term></item><item><term>cognition</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-12-21">Received</change><change when="2011-03-15">Registration</change><change when="2011-08-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/26CEF5A8C585D95DE1DC4C765107ECB1F441C629/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="100"><doi origin="wiley" registered="yes">10.1002/mds.v26.10</doi><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">10</numbering></numberingGroup><coverDate startDate="2011-08-15">15 August 2011</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="180" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23746</doi><idGroup><id type="unit" value="MDS23746"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2011 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2010-12-21"></event><event type="manuscriptRevised" date="2011-03-05"></event><event type="manuscriptAccepted" date="2011-03-15"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.0.1 mode:FullText" date="2011-12-15"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-05-24"></event><event type="publishedOnlineFinalForm" date="2011-08-26"></event><event type="firstOnline" date="2011-05-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1875</numbering><numbering type="pageLast">1880</numbering></numberingGroup><correspondenceTo>Beth Israel Medical Center, 10 Union Square East, Suite 5H, New York, NY 10003, USA</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23746.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="4"></count><count type="referenceTotal" number="49"></count><count type="wordTotal" number="5484"></count></countGroup><titleGroup><title type="main" xml:lang="en">Mood and cognition in leucine‐rich repeat kinase 2 G2019S Parkinson's disease<link href="#fn1"></link><link href="#fn2"></link></title><title type="short" xml:lang="en">Mood and Cognition in LRRK2 G2019S PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Vicki</givenNames><familyName>Shanker</familyName><degrees>MD</degrees></personName><contactDetails><email>vshanker@chpnet.org</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Mark</givenNames><familyName>Groves</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Gary</givenNames><familyName>Heiman</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Christina</givenNames><familyName>Palmese</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Rachel</givenNames><familyName>Saunders‐Pullman</familyName><degrees>MD, MPH</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Laurie</givenNames><familyName>Ozelius</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Deborah</givenNames><familyName>Raymond</familyName><degrees>MS</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Susan</givenNames><familyName>Bressman</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Beth Israel Medical Center, New York, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Rutgers University, Piscataway, New Jersey, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Mount Sinai Medical Center, New York, New York, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">leucine‐rich repeat kinase 2</keyword><keyword xml:id="kwd3">mood</keyword><keyword xml:id="kwd4">depression</keyword><keyword xml:id="kwd5">cognition</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The behavioral and cognitive features of the leucine‐rich repeat kinase G2019S mutation in Parkinson's disease in the Ashkenazi Jewish population are not well described; therefore, we sought to more systematically characterize these features using a semistructured psychiatric interview and neuropsychological testing. Twenty‐one Ashkenazi Jewish patients having the leucine‐rich repeat kinase G2019S mutation were compared with age‐ and sex‐matched Ashkenazi Jewish patients with Parkinson's disease without mutations. Although overall rates of affective disorders were not greater in mutation carriers, the carriers exhibited a 6‐fold increased risk of premorbid affective disorders (odds ratio, 6.0; <i>P</i> = .10), as determined by the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders–IV. Of interest, we identified 2 leucine‐rich repeat kinase carriers with bipolar disorder; no mutation‐negative subjects had this diagnosis. Performance on the Hopkins Verbal Learning Test–Revised, Judgment of Line Orientation, and Frontal Assessment Battery was consistent with previous reports and did not differ between groups. Study findings suggest a possible association between premorbid mood disorders and leucine‐rich repeat kinase Parkinson's disease, warranting further evaluation. © 2011 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Funding agencies: This project was supported by the Parkinson's Study Group, the National Parkinson's Foundation and the Michael J. Fox Foundation.</p></note><note xml:id="fn2"><p>Relevant conflicts of interest/financial disclosures: Nothing to report. Full financial disclosures and author roles may be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Mood and cognition in leucine‐rich repeat kinase 2 G2019S Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Mood and Cognition in LRRK2 G2019S PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Mood and cognition in leucine‐rich repeat kinase 2 G2019S Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Vicki</namePart><namePart type="family">Shanker</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Beth Israel Medical Center, New York, New York, USA</affiliation><description>Correspondence: Beth Israel Medical Center, 10 Union Square East, Suite 5H, New York, NY 10003, USA</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mark</namePart><namePart type="family">Groves</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Beth Israel Medical Center, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gary</namePart><namePart type="family">Heiman</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Rutgers University, Piscataway, New Jersey, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christina</namePart><namePart type="family">Palmese</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Beth Israel Medical Center, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Rachel</namePart><namePart type="family">Saunders‐Pullman</namePart><namePart type="termsOfAddress">MD, MPH</namePart><affiliation>Beth Israel Medical Center, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Laurie</namePart><namePart type="family">Ozelius</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Mount Sinai Medical Center, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Deborah</namePart><namePart type="family">Raymond</namePart><namePart type="termsOfAddress">MS</namePart><affiliation>Beth Israel Medical Center, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Susan</namePart><namePart type="family">Bressman</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Beth Israel Medical Center, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-08-15</dateIssued><dateCaptured encoding="w3cdtf">2010-12-21</dateCaptured><dateValid encoding="w3cdtf">2011-03-15</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">4</extent><extent unit="references">49</extent><extent unit="words">5484</extent></physicalDescription><abstract lang="en">The behavioral and cognitive features of the leucine‐rich repeat kinase G2019S mutation in Parkinson's disease in the Ashkenazi Jewish population are not well described; therefore, we sought to more systematically characterize these features using a semistructured psychiatric interview and neuropsychological testing. Twenty‐one Ashkenazi Jewish patients having the leucine‐rich repeat kinase G2019S mutation were compared with age‐ and sex‐matched Ashkenazi Jewish patients with Parkinson's disease without mutations. Although overall rates of affective disorders were not greater in mutation carriers, the carriers exhibited a 6‐fold increased risk of premorbid affective disorders (odds ratio, 6.0; P = .10), as determined by the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders–IV. Of interest, we identified 2 leucine‐rich repeat kinase carriers with bipolar disorder; no mutation‐negative subjects had this diagnosis. Performance on the Hopkins Verbal Learning Test–Revised, Judgment of Line Orientation, and Frontal Assessment Battery was consistent with previous reports and did not differ between groups. Study findings suggest a possible association between premorbid mood disorders and leucine‐rich repeat kinase Parkinson's disease, warranting further evaluation. © 2011 Movement Disorder Society</abstract><note type="content">*Funding agencies: This project was supported by the Parkinson's Study Group, the National Parkinson's Foundation and the Michael J. Fox Foundation.</note><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report. Full financial disclosures and author roles may be found in the online version of this article.</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>leucine‐rich repeat kinase 2</topic><topic>mood</topic><topic>depression</topic><topic>cognition</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>10</number></detail><extent unit="pages"><start>1875</start><end>1880</end><total>6</total></extent></part></relatedItem><identifier type="istex">26CEF5A8C585D95DE1DC4C765107ECB1F441C629</identifier><identifier type="DOI">10.1002/mds.23746</identifier><identifier type="ArticleID">MDS23746</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B05 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000B05 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:26CEF5A8C585D95DE1DC4C765107ECB1F441C629
|texte= Mood and cognition in leucine‐rich repeat kinase 2 G2019S Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |